Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: Current state-of-the science

• We discussed potential mechanism of action of NSAIDs.
• We discussed the effect of NSAID dose and treatment duration on outcomes of gastrointestinal tumors.
• We discussed the impact of epigenetic regulation on response to NSAID treatment.
• We discussed possible causes of conflicting results between observational and clinical studies.

Growing evidence from epidemiologic and preclinical studies suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal (GI) cancers, including esophageal, gastric, pancreatic, colorectal cancer, and hepatocellular carcinoma. However, there is also evidence indicating the absence of this benefit. The exact mechanism of NSAIDs’ action on GI tumors is not known. Although some studies have suggested inhibition of carcinogenesis by NSAIDs through suppression effect on inflammation-associated cyclooxygenase-2 (COX-2) expression, other studies have suggested COX-2-independent mechanisms. Herein, we summarize the current state of-the-science regarding NSAID benefit for patients with GI cancers.